You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFlibanserin
Accession NumberDB04908
TypeSmall Molecule
GroupsApproved
DescriptionFlibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
Structure
Thumb
Synonyms
BIMT-17
BIMT-17-BS
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Addyitablet, film coated100 mg/1oralSprout Pharmaceuticals, Inc.2015-08-18Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EctrisNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Flibanserin hydrochloride
ThumbNot applicableDBSALT001321
Categories
UNII37JK4STR6Z
CAS number167933-07-5
WeightAverage: 390.4021
Monoisotopic: 390.166745929
Chemical FormulaC20H21F3N4O
InChI KeyPPRRDFIXUUSXRA-UHFFFAOYSA-N
InChI
InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)
IUPAC Name
1-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-2,3-dihydro-1H-1,3-benzodiazol-2-one
SMILES
FC(F)(F)C1=CC(=CC=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenylpiperazine
  • Benzimidazole
  • Substituted aniline
  • Dialkylarylamine
  • N-alkylpiperazine
  • Aniline
  • Benzenoid
  • N-substituted imidazole
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Urea
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
PharmacodynamicsNot Available
Mechanism of actionFlibansetrin has high affinity for serotonin receptors in the brain: it acts as an agonist on 5-HT1A and an antagonist on 5-HT2A. In vivo, flibanserin binds equally to 5-HT1A and 5-HT2A receptors. However, under higher levels of brain 5-HT (i.e., under stress), flibanserin may occupy 5-HT2A receptors in higher proportion than 5-HT(1A) receptors. It may also moderately antagonize D4 (dopamine) receptors and 5-HT2B and 5-HTB2C. Its action on neurotransmitter receptors may contribute to reduction in serotonin levels and increase in dopamine and norepinephrine levels, all of which may play part in reward processing.
Related Articles
AbsorptionFlibanserin has an absolute oral availability of 33%.
Volume of distributionNot Available
Protein binding~98%, highly bound to proteins (mostly albumin) in serum.
Metabolism

Metabolism is primarily via CYP3A4, slightly CYP2C19. Minimal involvement of CYP1A2, CYP2B6, CYP2C8, CYP2C9 or CYP2D6. At least 35 metabolites of flibanserin are produced, 2 of which reach plasma concentrations as high as parent drug, however they are pharmacologically inactive.

Route of eliminationElimination via feces (51%) and urine (44%) following a single oral 50 mg dose of flibanserin solution.
Half life≈11 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9857
Caco-2 permeable-0.7652
P-glycoprotein substrateSubstrate0.6865
P-glycoprotein inhibitor IInhibitor0.8895
P-glycoprotein inhibitor IIInhibitor0.8741
Renal organic cation transporterInhibitor0.6378
CYP450 2C9 substrateNon-substrate0.7906
CYP450 2D6 substrateNon-substrate0.5905
CYP450 3A4 substrateSubstrate0.6954
CYP450 1A2 substrateInhibitor0.8379
CYP450 2C9 inhibitorNon-inhibitor0.7028
CYP450 2D6 inhibitorInhibitor0.5876
CYP450 2C19 inhibitorNon-inhibitor0.59
CYP450 3A4 inhibitorInhibitor0.7523
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9005
Ames testNon AMES toxic0.6798
CarcinogenicityNon-carcinogens0.9354
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6546 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6138
hERG inhibition (predictor II)Inhibitor0.9486
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tablet, film coatedoral100 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7151103 No2003-05-092023-05-09Us
US7420057 No2002-08-012022-08-01Us
US8227471 No2003-05-092023-05-09Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.178 mg/mLALOGPS
logP3.32ALOGPS
logP3.83ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)12.91ChemAxon
pKa (Strongest Basic)7.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area38.82 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity103.65 m3·mol-1ChemAxon
Polarizability38.69 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R: Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br J Pharmacol. 2003 Aug;139(7):1281-8. [PubMed:12890707 ]
  2. Scandroglio A, Monferini E, Borsini F: Ex vivo binding of flibanserin to serotonin 5-HT1A and 5-HT2A receptors. Pharmacol Res. 2001 Feb;43(2):179-83. [PubMed:11243720 ]
  3. Borsini F, Cesana R: Mechanism of action of flibanserin in the learned helplessness paradigm in rats. Eur J Pharmacol. 2001 Dec 14;433(1):81-9. [PubMed:11755137 ]
  4. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S: Pharmacology of flibanserin. CNS Drug Rev. 2002 Summer;8(2):117-42. [PubMed:12177684 ]
  5. Deeks ED: Flibanserin: First Global Approval. Drugs. 2015 Oct;75(15):1815-22. doi: 10.1007/s40265-015-0474-y. [PubMed:26412054 ]
  6. Stahl SM: Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. CNS Spectr. 2015 Feb;20(1):1-6. doi: 10.1017/S1092852914000832. Epub 2015 Feb 9. [PubMed:25659981 ]
External Links
ATC CodesG02CX02
AHFS Codes
  • 28:92
PDB EntriesNot Available
FDA labelDownload (788 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Flibanserin.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Flibanserin.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Flibanserin.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Flibanserin.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Flibanserin.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Flibanserin.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Flibanserin.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Flibanserin.
AlprazolamThe serum concentration of Flibanserin can be increased when it is combined with Alprazolam.
AlprazolamThe risk or severity of adverse effects can be increased when Flibanserin is combined with Alprazolam.
AmiodaroneThe serum concentration of Flibanserin can be increased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Flibanserin.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Flibanserin.
AmlodipineThe serum concentration of Flibanserin can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Flibanserin.
AmoxapineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Flibanserin.
AprepitantThe serum concentration of Flibanserin can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Flibanserin.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Flibanserin.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Flibanserin.
AtazanavirThe serum concentration of Flibanserin can be increased when it is combined with Atazanavir.
AtomoxetineThe serum concentration of Flibanserin can be increased when it is combined with Atomoxetine.
AtorvastatinThe serum concentration of Flibanserin can be increased when it is combined with Atorvastatin.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Flibanserin.
AzelastineFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Flibanserin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Flibanserin.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Flibanserin.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Flibanserin.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Flibanserin.
BexaroteneThe serum concentration of Flibanserin can be decreased when it is combined with Bexarotene.
BicalutamideThe serum concentration of Flibanserin can be increased when it is combined with Bicalutamide.
BoceprevirThe serum concentration of Flibanserin can be increased when it is combined with Boceprevir.
BortezomibThe serum concentration of Flibanserin can be increased when it is combined with Bortezomib.
BosentanThe serum concentration of Flibanserin can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Flibanserin is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.
BrimonidineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Flibanserin.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Flibanserin.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Flibanserin.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Flibanserin.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Flibanserin.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Flibanserin.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flibanserin.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Flibanserin.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Flibanserin.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Flibanserin.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Flibanserin.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flibanserin.
CarbamazepineThe serum concentration of Flibanserin can be decreased when it is combined with Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Flibanserin.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Flibanserin.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Flibanserin.
CeritinibThe serum concentration of Flibanserin can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Flibanserin.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Flibanserin.
ChloramphenicolThe serum concentration of Flibanserin can be increased when it is combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Flibanserin.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Flibanserin.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Flibanserin.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Flibanserin.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Flibanserin.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Flibanserin.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Flibanserin.
CilostazolThe serum concentration of Flibanserin can be increased when it is combined with Cilostazol.
CimetidineThe serum concentration of Flibanserin can be increased when it is combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Flibanserin.
CiprofloxacinThe serum concentration of Flibanserin can be increased when it is combined with Ciprofloxacin.
CitalopramThe risk or severity of adverse effects can be increased when Flibanserin is combined with Citalopram.
ClarithromycinThe serum concentration of Flibanserin can be increased when it is combined with Clarithromycin.
ClemastineThe serum concentration of Flibanserin can be increased when it is combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Flibanserin.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Flibanserin.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Flibanserin.
ClomipramineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Flibanserin.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Flibanserin.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flibanserin.
ClotrimazoleThe serum concentration of Flibanserin can be increased when it is combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Flibanserin.
CobicistatThe serum concentration of Flibanserin can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Flibanserin.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Flibanserin.
ConivaptanThe serum concentration of Flibanserin can be increased when it is combined with Conivaptan.
CrizotinibThe serum concentration of Flibanserin can be increased when it is combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Flibanserin.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flibanserin.
CyclosporineThe serum concentration of Flibanserin can be increased when it is combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Flibanserin.
DabrafenibThe serum concentration of Flibanserin can be decreased when it is combined with Dabrafenib.
DalfopristinThe serum concentration of Flibanserin can be increased when it is combined with Dalfopristin.
DanazolThe serum concentration of Flibanserin can be increased when it is combined with Danazol.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Flibanserin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flibanserin.
DapoxetineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Dapoxetine.
DarunavirThe serum concentration of Flibanserin can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Flibanserin can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Flibanserin can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Flibanserin can be increased when it is combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Flibanserin.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Flibanserin.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Flibanserin.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Flibanserin.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Flibanserin.
DexamethasoneThe serum concentration of Flibanserin can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flibanserin.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Flibanserin.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Flibanserin.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Flibanserin.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Flibanserin.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Flibanserin.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Flibanserin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Flibanserin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Flibanserin.
DihydroergotamineThe serum concentration of Flibanserin can be increased when it is combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Flibanserin.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Flibanserin.
DiltiazemThe serum concentration of Flibanserin can be increased when it is combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Flibanserin.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Flibanserin.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Flibanserin.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Flibanserin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Flibanserin.
DoxycyclineThe serum concentration of Flibanserin can be increased when it is combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.
DoxylamineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Flibanserin.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.
DronedaroneThe serum concentration of Flibanserin can be increased when it is combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Flibanserin.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Flibanserin.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flibanserin.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Flibanserin.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Flibanserin.
EfavirenzThe serum concentration of Flibanserin can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Flibanserin is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Flibanserin.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Flibanserin.
EnzalutamideThe serum concentration of Flibanserin can be decreased when it is combined with Enzalutamide.
ErythromycinThe serum concentration of Flibanserin can be increased when it is combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Flibanserin is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Flibanserin can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Flibanserin.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flibanserin.
EthanolFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolEthanol may increase the hypotensive activities of Flibanserin.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flibanserin.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Flibanserin.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Flibanserin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Flibanserin.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Flibanserin.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Flibanserin.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Flibanserin.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Flibanserin.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Flibanserin.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Flibanserin.
EtoperidoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Flibanserin.
EtravirineThe serum concentration of Flibanserin can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Flibanserin.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Flibanserin.
FenfluramineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flibanserin.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Flibanserin.
FluconazoleThe serum concentration of Flibanserin can be increased when it is combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Flibanserin.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Flibanserin.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Flibanserin.
FluoxetineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Flibanserin.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flibanserin.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Flibanserin.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Flibanserin.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Flibanserin.
FluvoxamineThe serum concentration of Flibanserin can be increased when it is combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fluvoxamine.
FosamprenavirThe serum concentration of Flibanserin can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Flibanserin can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Flibanserin can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Flibanserin.
Fusidic AcidThe serum concentration of Flibanserin can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Flibanserin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Flibanserin is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Flibanserin.
GemfibrozilThe serum concentration of Flibanserin can be increased when it is combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Flibanserin.
Glycerol PhenylbutyrateThe serum concentration of Flibanserin can be increased when it is combined with Glycerol Phenylbutyrate.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Flibanserin.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Flibanserin.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Flibanserin.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Flibanserin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Flibanserin.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Flibanserin.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Flibanserin.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flibanserin.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.
HydroxyzineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Hydroxyzine.
IdelalisibThe serum concentration of Flibanserin can be increased when it is combined with Idelalisib.
IloperidoneThe serum concentration of Flibanserin can be increased when it is combined with Iloperidone.
IloperidoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Iloperidone.
ImatinibThe serum concentration of Flibanserin can be increased when it is combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Flibanserin.
IndalpineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Indalpine.
IndinavirThe serum concentration of Flibanserin can be increased when it is combined with Indinavir.
IsavuconazoniumThe serum concentration of Flibanserin can be increased when it is combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Flibanserin.
IsoniazidThe serum concentration of Flibanserin can be increased when it is combined with Isoniazid.
IsradipineThe serum concentration of Flibanserin can be increased when it is combined with Isradipine.
ItraconazoleThe serum concentration of Flibanserin can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Flibanserin can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Flibanserin.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Flibanserin.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Flibanserin.
KetoconazoleThe serum concentration of Flibanserin can be increased when it is combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Flibanserin.
LapatinibThe serum concentration of Flibanserin can be increased when it is combined with Lapatinib.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Flibanserin.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Flibanserin.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Flibanserin.
LevocetirizineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Flibanserin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Flibanserin.
LevomilnacipranThe risk or severity of adverse effects can be increased when Flibanserin is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Flibanserin.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Flibanserin.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Flibanserin.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Flibanserin.
LomitapideThe serum concentration of Flibanserin can be increased when it is combined with Lomitapide.
LopinavirThe serum concentration of Flibanserin can be increased when it is combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Flibanserin.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Flibanserin.
LovastatinThe serum concentration of Flibanserin can be increased when it is combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Flibanserin.
Lu AA21004The risk or severity of adverse effects can be increased when Flibanserin is combined with Lu AA21004.
LuliconazoleThe serum concentration of Flibanserin can be increased when it is combined with Luliconazole.
LurasidoneThe serum concentration of Flibanserin can be increased when it is combined with Lurasidone.
LurasidoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Flibanserin is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Flibanserin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Flibanserin.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Flibanserin.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Flibanserin.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Flibanserin.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Flibanserin.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flibanserin.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Flibanserin.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Flibanserin.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Flibanserin.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Flibanserin.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Flibanserin.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Flibanserin.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Flibanserin.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Flibanserin.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Flibanserin.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Flibanserin.
MethsuximideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Flibanserin.
MetyrosineFlibanserin may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Flibanserin.
MifepristoneThe serum concentration of Flibanserin can be increased when it is combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Flibanserin is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.
MirtazapineFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Flibanserin.
MitotaneThe serum concentration of Flibanserin can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Flibanserin can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Flibanserin.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Flibanserin.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.
NabiloneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Nabilone.
NafcillinThe serum concentration of Flibanserin can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Flibanserin.
NefazodoneThe serum concentration of Flibanserin can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Flibanserin can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Flibanserin can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Flibanserin can be increased when it is combined with Nevirapine.
NicardipineThe serum concentration of Flibanserin can be increased when it is combined with Nicardipine.
NilotinibThe serum concentration of Flibanserin can be increased when it is combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Flibanserin.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Flibanserin.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Flibanserin.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Flibanserin.
OlanzapineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Olanzapine.
OlaparibThe serum concentration of Flibanserin can be increased when it is combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flibanserin.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Flibanserin.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Flibanserin.
OrphenadrineFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Flibanserin.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Flibanserin.
OsimertinibThe serum concentration of Flibanserin can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Flibanserin.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Flibanserin.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Flibanserin.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flibanserin.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Flibanserin.
PalbociclibThe serum concentration of Flibanserin can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Flibanserin.
ParaldehydeFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Flibanserin.
ParoxetineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Paroxetine.
PazopanibThe serum concentration of Flibanserin can be increased when it is combined with Pazopanib.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flibanserin.
PentobarbitalThe serum concentration of Flibanserin can be decreased when it is combined with Pentobarbital.
PentobarbitalThe risk or severity of adverse effects can be increased when Flibanserin is combined with Pentobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Flibanserin is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Flibanserin.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Flibanserin.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Flibanserin.
PhenobarbitalThe serum concentration of Flibanserin can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Flibanserin is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Flibanserin.
PhenytoinThe serum concentration of Flibanserin can be decreased when it is combined with Phenytoin.
PhenytoinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Flibanserin.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Flibanserin.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Flibanserin.
PizotifenThe risk or severity of adverse effects can be increased when Flibanserin is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Pomalidomide.
PosaconazoleThe serum concentration of Flibanserin can be increased when it is combined with Posaconazole.
PramipexoleFlibanserin may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Flibanserin.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Flibanserin.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Flibanserin.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Flibanserin.
PrimidoneThe serum concentration of Flibanserin can be decreased when it is combined with Primidone.
PrimidoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Flibanserin.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flibanserin.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Flibanserin.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Flibanserin.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Flibanserin.
PropofolThe serum concentration of Flibanserin can be increased when it is combined with Propofol.
PropofolThe risk or severity of adverse effects can be increased when Flibanserin is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Flibanserin.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Flibanserin.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Flibanserin.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Flibanserin.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flibanserin.
QuinidineThe serum concentration of Flibanserin can be increased when it is combined with Quinidine.
QuinupristinThe serum concentration of Flibanserin can be increased when it is combined with Quinupristin.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Flibanserin.
RanolazineThe serum concentration of Flibanserin can be increased when it is combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Flibanserin.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flibanserin.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Flibanserin.
RifabutinThe serum concentration of Flibanserin can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Flibanserin can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Flibanserin can be decreased when it is combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Flibanserin.
RitonavirThe serum concentration of Flibanserin can be increased when it is combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Flibanserin.
RopiniroleFlibanserin may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Flibanserin.
RotigotineFlibanserin may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Flibanserin.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Flibanserin.
SaquinavirThe serum concentration of Flibanserin can be increased when it is combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Flibanserin.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flibanserin.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Flibanserin.
SertralineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Flibanserin.
SildenafilThe serum concentration of Flibanserin can be increased when it is combined with Sildenafil.
SiltuximabThe serum concentration of Flibanserin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Flibanserin can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Flibanserin.
St. John's WortThe serum concentration of Flibanserin can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Flibanserin can be increased when it is combined with Stiripentol.
StiripentolThe risk or severity of adverse effects can be increased when Flibanserin is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flibanserin.
SulfisoxazoleThe serum concentration of Flibanserin can be increased when it is combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Flibanserin.
SuvorexantThe risk or severity of adverse effects can be increased when Flibanserin is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Flibanserin is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Flibanserin is combined with Tasimelteon.
TelaprevirThe serum concentration of Flibanserin can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Flibanserin can be increased when it is combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Flibanserin.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Flibanserin.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Flibanserin.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Flibanserin.
ThalidomideFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Flibanserin.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Flibanserin.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Flibanserin.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Flibanserin.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Flibanserin.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Flibanserin.
TicagrelorThe serum concentration of Flibanserin can be increased when it is combined with Ticagrelor.
TiclopidineThe serum concentration of Flibanserin can be increased when it is combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Flibanserin.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Flibanserin.
TocilizumabThe serum concentration of Flibanserin can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Flibanserin.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Flibanserin.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Flibanserin.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Flibanserin.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Flibanserin.
TrazodoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Flibanserin.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flibanserin.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flibanserin.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Flibanserin.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Flibanserin.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Flibanserin.
VenlafaxineThe serum concentration of Flibanserin can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Flibanserin can be increased when it is combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Flibanserin.
VilazodoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Vilazodone.
VoriconazoleThe serum concentration of Flibanserin can be increased when it is combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Flibanserin.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Flibanserin.
ZiconotideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Zimelidine.
ZiprasidoneThe serum concentration of Flibanserin can be increased when it is combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Flibanserin.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Flibanserin.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Flibanserin.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Flibanserin.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Flibanserin.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Flibanserin.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R: Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br J Pharmacol. 2003 Aug;139(7):1281-8. [PubMed:12890707 ]
  2. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S: Pharmacology of flibanserin. CNS Drug Rev. 2002 Summer;8(2):117-42. [PubMed:12177684 ]
  3. Deeks ED: Flibanserin: First Global Approval. Drugs. 2015 Oct;75(15):1815-22. doi: 10.1007/s40265-015-0474-y. [PubMed:26412054 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S: Pharmacology of flibanserin. CNS Drug Rev. 2002 Summer;8(2):117-42. [PubMed:12177684 ]
  2. Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R: Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br J Pharmacol. 2003 Aug;139(7):1281-8. [PubMed:12890707 ]
  3. Deeks ED: Flibanserin: First Global Approval. Drugs. 2015 Oct;75(15):1815-22. doi: 10.1007/s40265-015-0474-y. [PubMed:26412054 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S: Pharmacology of flibanserin. CNS Drug Rev. 2002 Summer;8(2):117-42. [PubMed:12177684 ]
  2. Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R: Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br J Pharmacol. 2003 Aug;139(7):1281-8. [PubMed:12890707 ]
  3. Deeks ED: Flibanserin: First Global Approval. Drugs. 2015 Oct;75(15):1815-22. doi: 10.1007/s40265-015-0474-y. [PubMed:26412054 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Deeks ED: Flibanserin: First Global Approval. Drugs. 2015 Oct;75(15):1815-22. doi: 10.1007/s40265-015-0474-y. [PubMed:26412054 ]
Comments
comments powered by Disqus
Drug created on October 21, 2007 16:23 / Updated on September 25, 2016 02:17